SCHEMBL4032637

SCHEMBL4032637

COc1ccc(C(=O)N2C3CCC(C3)C2C(=O)O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.51
CHRNB2 P17787 2/20 0.45
CHRNB4 P30926 2/20 0.45
CHRNA3 P32297 2/20 0.45
CHRNA7 P36544 2/20 0.45
CHRNA4 P43681 2/20 0.45
POLB P06746 1/20 0.45
HPGD P15428 2/20 0.44
ELOVL6 Q9H5J4 1/20 0.43
ALDH1A1 P00352 4/20 0.43
LMNA P02545 3/20 0.43
HIF1A Q16665 1/20 0.43
GRM3 Q14832 2/20 0.42
HSD11B1 P28845 2/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4035088 0.86 CHRNB2 (0.42) GAACHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL4026248 0.84 ALDH1A1 (0.45) GAACHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL4031887 0.75 CYP3A4 (0.54) ALDH1A1
SCHEMBL6480554 0.74 ALDH1A1 (0.59) GAAHPGDALDH1A1LMNAKDM4E
SCHEMBL4031087 0.74 ALDH1A1 (0.59) GAAHPGDALDH1A1LMNAKDM4E
SCHEMBL6492319 0.74 ALDH1A1 (0.59) GAAHPGDALDH1A1LMNAKDM4E
SCHEMBL17350908 0.72 ALDH1A1 (0.53) POLBHPGDALDH1A1LMNAHIF1A
SCHEMBL10243899 0.72 ALDH1A1 (0.53) POLBHPGDALDH1A1LMNAHIF1A
SCHEMBL1909477 0.71 GAA (0.58) GAAPOLBHPGDALDH1A1LMNA
P-Anisic Acid SCHEMBL27396257 0.70 CA1 (0.71) GAAPOLBALDH1A1LMNACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1452527-B1 AZABICYCLO COMPOUND, MATRIX METALLOPROTEASE INHIBITOR, AND SKIN PREPARATION SHISEIDO CO LTD (JP) 2009-03-04 EP disclosed
US-7176217-B2 Azabicyclo compound matrix metalloprotease inhibitor and skin preparation SHISEIDO CO., LTD. (JP) 2007-02-13 US disclosed
US-20050009808-A1 Azabicyclo compound matrix metalloprotease inibitor and skin preparation SHISEIDO CO., LTD. (JP) 2005-01-13 US disclosed
EP-1452527-A1 AZABICYCLO COMPOUND, MATRIX METALLOPROTEASE INHIBITOR, AND SKIN PREPARATION Shiseido Co., Ltd. (JP) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009808-A1 Azabicyclo compound matrix metalloprotease inibitor and skin preparation MMP1, MMP16, MMP9 GAA 1852/4885CHRNB2 2163/4885CHRNB4 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.